Navigation Links
Just 4 months of hormone therapy can delay prostate cancer growth by up to 8 years
Date:1/2/2008

Alexandria, VAResearchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight yearsespecially the development of bone metastasesand increased survival in older men with potentially aggressive prostate cancer. This neoadjuvant hormonal therapy may allow men most at risk of developing bone metastases avoid long-term hormonal therapy later on. Furthermore, the short-term hormonal therapy did not increase the risk of cardiovascular diseasea potential side effect of long-term hormonal therapy. The study is being published online January 2 in the Journal of Clinical Oncology (JCO).

Hormonal therapycalled androgen deprivation therapy (ADT)lowers levels of cancer-fueling testosterone in the blood. It is an important treatment option for men with prostate cancer that continues to progress despite initial treatment with surgery, radiation therapy, or chemotherapy, but has been associated with side effects such as bone loss, osteoporosis, depression and an increase in cardiovascular risk factors (including blood lipids, abdominal obesity and a syndrome associated with diabetes).

This study demonstrates that the benefits of short-term hormonal therapy for men receiving radiation therapy for prostate cancer far outweigh the risks, said lead author Mack Roach III, MD, professor and chair of radiation oncology and professor of urology at the University of California, San Francisco. While four months of hormonal therapy isnt enough to cause significant side effects, we found that it can delay the development of bone metastasis by as many as eight years, which is very significant.

Starting in 1987, Radiation Therapy Oncology Group researchers studied 224 men with high-risk prostate cancer who received ADT (goserelin and flutamide) before and concurrent with external beam radiation therapy, and 232 men with the disease who received radiation therapy alone. After 13 years of follow up, they found better 10-year disease-specific death rates (the rate of death from prostate cancer) for men who received ADT plus radiation (23 percent versus 36 percent of the radiation-only group), disease metastasis rates (35 percent versus 47 percent), disease-free survival (the percentage of men free of cancer at 10 years; 11 percent versus 3 percent) and biochemical failure rates (a rise in PSA levels; 65 percent versus 80 percent).

Among men who received neoadjuvant hormonal therapy, there was up to an eight-year delay in the time it took 40 percent of patients to develop bone metastases compared with men receiving radiation alone. Men who develop bone metastases often require long-term hormonal therapy, which can increase their risk for side effects. So by taking a little bit of hormonal therapy early, patients may avoid having to take a lot of it later, added Dr. Roach.

Fatal cardiac events occurred in 12 percent of patients in the ADT group compared with 9 percent of the radiation-only groupa difference that was not statistically significant.


'/>"/>

Contact: Tiffany Reynolds
reynoldt@asco.org
703-519-1423
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. portionpals(R) Sales Reach a Whopping 250,000 Units in 3 Months!
2. Experts propose cholesterol tests at 15 months of age
3. Florida Doctor Sentenced to 18 Months in Prison for Medicare Fraud
4. Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months
5. Wyeth Reports Earnings Results for the 2007 Third Quarter and First Nine Months
6. Lincare Holdings Inc. Announces Third Quarter and First Nine Months 2007 Financial Results
7. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
8. Treadmill training helps Down syndrome babies walk months earlier
9. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007
10. MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007
11. Chindex International, Inc. Announces Results for the Quarter and Six Months Ended September 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... , ... The 12th session of the Silicon Valley BioTalks will take place ... CA. This Bay Area biotech event will focus on “Setting Up Early Stage Clinical ... company Hallux, biopharma Apexigen, Contract Research Organization (CRO) Experien Group, and Electronic Data Capture ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We are very pleased to ... Advisors. “Brad brings significant experience advising healthcare provider clients throughout the country. As ... implementation of MACRA, we believe that continuing to add professionals with deep experience ...
(Date:5/25/2016)... ... 25, 2016 , ... The Georgia State University College of Law new building ... Design Commission. , The annual award recognizes projects, programs, individuals and organizations that have ... of its physical heritage and the balance between the old and the new. , ...
(Date:5/25/2016)... Marne, Michigan (PRWEB) , ... May 25, 2016 ... ... abuse located in Central Michigan, has produced another video highlighting one of the ... their Martial Arts class. Sensei Ed Taylor, a 5 th Degree Black Belt ...
(Date:5/25/2016)... ... 25, 2016 , ... According to an article published May 5th on The Daily ... their breath. In fact, it found that more than a third cited unappealing breath a ... by pungent foods or a failure to brush after meals, can typically be attributed to ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today ... co-development agreement with Therawis Diagnostics GmbH to develop and commercialize ... develop and market PITX2 as a marker to predict effectiveness ... cancer patients. "We are pleased to partner with ...
(Date:5/25/2016)...  According to Kalorama Information, the world market ... Though these are challenging times in the market, ... for companies that remain optimistic and seek innovation.  ... prospects medical device companies spend a higher percentage ... than do companies in other industries.  Also, in ...
(Date:5/25/2016)... CORAL SPRINGS, Florida , May 25, 2016 /PRNewswire/ ... Marijuana Business Conference & Expo earlier this month, the ... undeniable. As revenues continue to climb into the billions, ... to the newly released 4th Edition State of Legal ... New Frontier, a cannabis-focused data-analysis firm, much of the ...
Breaking Medicine Technology: